证券代码：300138 证券简称：晨光生物 编号：2022-001 晨光生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|------------------------------|-------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类 别 | □新闻发布会 □路演活动 | | | | □现场参观 | □一对一沟通 | | | √其他 （电话会议） | | | 参与单位名称及人 | | 天风证券吴立、天风证券林逸丹、工银瑞信基金袁辰昱、 嘉实基金谢泽林、华夏基金刘睿聪、中银基金王寒、诺安 | | 员姓名 | 勇、景林资产雨晨等 | 基金曾广坤、长江养老李泽、信诚人寿万力、中再资产赵 48 位投资者 | | | | | | 时间 | 2022 年 1 月 25 日 | ...

证券代码：300138 证券简称：晨光生物 编号：2022-002 1 | --- | --- | --- | |-------------------------|----------------------------------------|------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类 别 | □新闻发布会 □路演活动 | | | | □现场参观 | □一对一沟通 | | | √其他 （电话会议） | | | 参与单位名称及人 员姓名 | 盈周武等 8 位投资者 | 长城证券刘鹏、长城证券卢潇航、诺安基金耿诺、华夏久 | | 时间 | 2022 年 1 月 25 日 | | | | 河北省邯郸市曲周县城晨光路 | 1 号会议室 | | 地点 | 其他各电话会议方处不同地点 | | | 上市公司接待人员 | 董办主任周顺燕 | | | | 一、 2021 年经营情况介绍 | | | | 二、投资者提问与回答 | 1、请问公司赞比亚种 ...

证券代码：300138 证券简称：晨光生物 编号：2022-015 | --- | --- | --- | |-------------------------|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类 别 | □新闻发布会 □路演活动 | | | | □现场参观 | □一对一沟通 | | | √其他 （电话会议） | | | 参与单位名称及人 员姓名 | 金张海波等 25 位投资者 | 长城证券刘鹏、长城证券卢潇航、诺安基金耿诺、泰达宏 利基金周少博、阳光资产方圆、宝盈基金张若伦、湘财基 | | | | | | 时间 | 2022 年 10 月 27 日 | | | 地点 | 河北省邯郸市曲周县城晨光路 其他各电话会议方处不 ...

晨光生物科技集团股份有限公司 2022 年第三季度报告 证券代码：300138 证券简称：晨光生物 公告编号：2022-119 晨光生物科技集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|--------------------------|- ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 3,227,191,537.69, representing a 53.74% increase compared to CNY 2,099,150,619.43 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 240,397,801.18, up 27.40% from CNY 188,698,023.48 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 211,485,971.37, reflecting a 31.43% increase from CNY 160,915,538.86 year-on-year[23]. - The net cash flow from operating activities was CNY 963,901,233.43, an increase of 23.04% compared to CNY 783,395,394.01 in the same period last year[23]. - The total assets at the end of the reporting period were CNY 6,174,833,693.11, a 3.69% increase from CNY 5,955,165,411.81 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were CNY 2,967,267,210.06, up 6.53% from CNY 2,785,482,526.20 at the end of the previous year[23]. - The basic earnings per share increased to CNY 0.45, an 18.42% rise from CNY 0.38 in the same period last year[23]. - The diluted earnings per share also stood at CNY 0.45, reflecting an 18.42% increase compared to CNY 0.38 in the previous year[23]. - The weighted average return on equity was 8.29%, up from 7.77% in the same period last year[23]. Market Trends and Industry Insights - The plant extract industry in China saw an export value of $3.03 billion in 2021, representing a year-on-year growth of 23.9%[32]. - In the first half of 2022, the export value of plant extracts reached $1.765 billion, with a year-on-year increase of 28.19%[32]. - The global market for plant extracts is projected to reach $59.4 billion by 2025, indicating significant growth potential[34]. - The restaurant industry in China rebounded in 2021, achieving a revenue of ¥46,895 billion, which is an 18.6% increase year-on-year[33]. - The sweetener market is experiencing growth, with stevia as a high-sweetness, low-calorie natural sweetener gaining traction[33]. - The global natural food coloring market is projected to reach 2.5 billion USD by 2025, driven by the shift from synthetic to natural colors[40]. - The penetration rate of pepper extract in the restaurant industry is currently below 2%, indicating significant growth potential[42]. - The market for plant-based feed additives is expected to grow rapidly due to the implementation of anti-antibiotic policies in 2020[47]. Product Development and R&D - The company aims to develop ten products that rank first or among the top globally, leveraging its technological R&D and industrial production capabilities[39]. - The company employs a market-oriented R&D model to ensure product development aligns with market feedback and trends[36]. - The company has a research and development team of over 100 people and has received 78 technology awards, including two national science and technology progress second prizes[47]. - The company is conducting various R&D projects, including the optimization of extraction processes for chili, stevia, and rosemary, aimed at improving product quality and market competitiveness[52][54]. - The company is developing new products, including microencapsulated products and alternative anti-products, to diversify its product offerings and create new profit growth points[54]. Operational Strategies and Supply Chain - The company has established raw material bases in Xinjiang, Yunnan, and India, implementing a "farmhouse + government + enterprise" model for raw material cultivation and procurement, ensuring production stability[36]. - The company has established a complete procurement, R&D, production, and sales model, continuously improving its operational strategies based on market demand[35]. - The company has established strategic partnerships with core suppliers, enhancing the stability of raw material supply through a "farmer + government + enterprise" model[81]. - The company has increased its procurement of raw materials from India, improving production and inventory levels for chili extract products[71]. Environmental and Social Responsibility - The company has increased investment in environmental protection facilities and established a strict environmental monitoring system to comply with rising environmental standards[126]. - The company has implemented measures to reduce carbon emissions, including the use of liquid CO2 in production and the adoption of natural gas to lower CO2 and nitrogen oxide emissions[145]. - The company has actively participated in social responsibility initiatives, donating over 140,000 RMB in pandemic prevention materials and supporting local education and public services in India and Zambia[147]. - The company has established wastewater treatment and dust removal facilities, ensuring that wastewater is treated and partially reused for landscaping[141]. Financial Management and Investments - The company reported a year-on-year revenue increase of 80.74% for cottonseed and cottonseed products, which contributed over 50% to the total revenue[65]. - The company has received approval for its stock to be listed and directed issued on the National Equities Exchange and Quotations system, allowing for the issuance of up to 15,870,356 new shares within 12 months from June 29, 2022[188][189]. - The company has been actively involved in securing bank loans, with multiple instances of increasing guarantee amounts reported throughout the year, indicating a focus on financial leverage[190][191]. - The company has provided guarantees for its subsidiaries' equipment leasing and subsequent repurchase arrangements, indicating a commitment to supporting its subsidiaries' operational needs[184]. Shareholder and Governance Matters - The company has fulfilled all commitments made by controlling shareholders and related parties as of the end of the reporting period[150]. - The commitments include not engaging in any competitive business activities with the company and ensuring the protection of shareholder interests[150]. - The company has established measures to ensure the legal and reasonable exercise of shareholder rights[150]. - The company has a clear strategy to mitigate potential conflicts of interest from shareholders[150]. Subsidiary Performance - The subsidiary "Morning Light Biotechnology Group Tumushuke Co., Ltd." reported a revenue increase of 483.48%, operating profit increase of 1387.31%, and net profit increase of 1814.67% compared to the same period last year, primarily due to rising sales prices and increased sales volume[120]. - The subsidiary "Morning Light Biotechnology Group Karamay Co., Ltd." experienced a revenue growth of 15.10%, operating profit growth of 3.97%, and net profit growth of 2.02% year-on-year, attributed to increased sales prices and volume[120]. - The subsidiary "Morning Light Biotechnology Group Yanqi Co., Ltd." reported a sales revenue increase of 66.27%, but a decline in operating profit and net profit by 27.82% and 26.62% respectively, due to cost fluctuations in internal processing business[121].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,584,746,474.76, representing a 56.61% increase compared to CNY 1,011,910,611.71 in the same period last year[5]. - Net profit attributable to shareholders was CNY 106,924,931.52, up 37.00% from CNY 78,047,185.06 year-on-year[5]. - Basic and diluted earnings per share increased by 32.48% to CNY 0.2007 from CNY 0.1515 in the same period last year[5]. - Total operating revenue for the first quarter reached ¥1,584,746,474.76, a significant increase of 56.2% compared to ¥1,011,910,611.71 in the previous year[49]. - Net profit for the quarter was ¥106,869,101.26, representing a 37.5% increase from ¥77,680,503.48 year-over-year[49]. - The net profit attributable to the parent company was approximately ¥106.92 million, an increase from ¥78.05 million in the previous period, representing a growth of 37%[53]. - The total comprehensive income attributable to the parent company was approximately ¥102.53 million, compared to ¥80.63 million in the previous period, reflecting a growth of 27%[53]. Cash Flow - The net cash flow from operating activities was negative CNY 28,312,350.64, a decrease of 107.78% compared to CNY 364,115,945.78 in the previous year[5]. - Cash inflows from operating activities totaled approximately ¥1.85 billion, up from ¥1.18 billion in the previous period, indicating a growth of 57%[54]. - Cash outflows from operating activities amounted to approximately ¥1.88 billion, compared to ¥812.07 million in the previous period, resulting in a net cash flow from operating activities of approximately -¥28.31 million, down from ¥364.12 million[57]. - Cash inflows from financing activities were approximately ¥585.93 million, significantly higher than ¥62.67 million in the previous period, showing an increase of 834%[60]. - The net cash flow from financing activities was approximately -¥33.52 million, compared to -¥203.46 million in the previous period, indicating an improvement[60]. - The cash and cash equivalents at the end of the period were approximately ¥319.92 million, down from ¥377.32 million in the previous period[60]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,173,266,717.34, a 3.66% increase from CNY 5,955,165,411.81 at the end of the previous year[7]. - Total liabilities rose to ¥3,287,407,231.71, up from ¥3,171,782,359.89, indicating an increase of 3.6%[45]. - The company's total liabilities increased, with contract liabilities rising by 25.81% due to expanded sales activities[13]. Research and Development - Research and development expenses grew by 29.91%, reflecting the company's commitment to innovation and product development[14]. - Research and development expenses for the quarter were ¥17,432,842.73, up 30.5% from ¥13,419,264.15 in the previous year[49]. - The company is advancing several R&D projects, including improvements in chili red pigment production processes aimed at enhancing product yield and quality[32]. - The company is optimizing the production process for stevia and marigold, with the goal of achieving large-scale production to meet market demand[32]. - The company has completed the pilot test verification for the development of rutin products and is currently conducting summary analysis[35]. Market and Sales - The company experienced a 60.50% increase in cash received from sales of goods and services compared to the previous year[18]. - The sales volume of chili red pigment increased by over 30% year-on-year, with sales revenue growing by over 40% due to rising raw material costs[32]. - The sweet stevia sugar sales revenue exceeded 60 million yuan, achieving a year-on-year doubling in revenue[32]. - The health food business generated over 20 million yuan in revenue, leveraging the company's raw material and production advantages[32]. - The company is focusing on market expansion and risk control in its cottonseed business, with orderly progress in its New Third Board listing[32]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,306, with the largest shareholder holding 18.43%[21]. - The largest shareholder, Lu Qingguo, held 98,196,051 shares, with 73,647,038 shares pledged[24]. - The total number of restricted shares at the beginning of the period was 107,093,569, with 1,443,822 shares released during the period[28]. - The company has a commitment from certain executives not to transfer their shares for specified periods after leaving their positions[28]. Other Financial Metrics - The weighted average return on equity was 3.77%, up from 3.47% in the previous year, indicating improved profitability[5]. - Cash dividends and interest payments increased by 60.64% year-on-year, attributed to the growth in financing scale and corresponding interest expenses[19]. - The company reported a gross profit margin of approximately 13.5% for the quarter, compared to 12.2% in the same period last year[49]. - The total equity attributable to shareholders increased to ¥2,888,284,610.78 from ¥2,785,482,526.20, reflecting a growth of 3.7%[45].

晨光生物科技集团股份有限公司 2021 年年度报告全文 晨光生物科技集团股份有限公司 2021 年年度报告 2022-022 2022 年 03 月 1 晨光生物科技集团股份有限公司 2021 年年度报告全文 本公积金向全体股东每 10 股转增 0 股。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，投 资者及相关人士应当对此保持足够的风险认识，并且应当理解计划、预测与承 诺之间的差异。 报告期，公司无新增加的可能对公司下一报告期经营产生不利影响的重大 | --- | |-------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2021 reached ¥1,105,865,310.31, representing a year-on-year increase of 25.38%[4] - Net profit attributable to shareholders was ¥70,914,808.74, up 32.29% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥67,025,215.57, reflecting a significant increase of 74.63% year-on-year[4] - Total operating revenue for Q3 2021 reached ¥3,205,015,929.74, an increase of 18.3% compared to ¥2,708,004,737.07 in the same period last year[56] - Net profit rose to ¥258,946,990.39, compared to ¥204,195,444.07 in the previous period, marking an increase of about 26.73%[59] - The total profit increased to ¥291,522,245.48 from ¥239,316,633.13, showing a growth of approximately 21.83%[59] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,142,085,245.23, a decrease of 11.01% from the end of the previous year[4] - Total liabilities reduced to ¥1,442,909,818.40, down 44% from ¥2,594,943,316.89, indicating improved financial stability[55] - The company's equity attributable to shareholders increased to ¥2,701,001,130.64 from ¥2,064,141,483.17, a growth of 30.9%[55] - Accounts receivable decreased to ¥233,937,292.60 from ¥295,103,396.78, a reduction of 20.8% year-over-year[48] - Inventory levels significantly dropped to ¥902,109,371.50, down 49.7% from ¥1,792,640,449.91 at the end of 2020[48] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥1,282,564,727.68, showing a decline of 8.69% compared to the previous year[4] - Cash inflow from operating activities totaled ¥3,590,017,777.69, compared to ¥3,252,429,712.19 in the previous period, an increase of about 10.39%[63] - Cash received from financing activities decreased by 66.67% year-on-year, primarily due to the absence of new convertible bond issuances in the reporting period[18] - Cash inflow from investment activities was CNY 701,399,445.34, significantly higher than CNY 4,373,281.46 in the previous period[1] Investments and Growth - The company plans to invest 26.08 million USD in Zambia to expand its natural colorant project and establish a lutein extraction factory[28] - Investment income increased by 150.27% year-on-year, driven by effective cash management and improved performance from associated companies[12] - The company is actively developing a health food business with a focus on OEM models, achieving sales revenue of over 35 million yuan, which is more than double the previous year[28] - The company has a strategy to expand its market presence through potential acquisitions and partnerships, as indicated by its recent activities[45] Research and Development - The company is implementing a market-oriented R&D model to enhance product stability and improve extraction rates for various natural products[28] - The company is actively collaborating with several universities and research institutions, including China Agricultural University and Zhejiang University, to enhance its R&D capabilities[29] - The company has completed small-scale process development for the Rutin product and is currently conducting pilot tests[32] - The company has developed a new product based on the extraction of tea polyphenols, which meets market demand and has completed trial production[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,315, an increase from 12,882 at the end of July 2021[38] - The largest shareholder, Lu Qingguo, holds 18.43% of the shares, amounting to 98,196,051 shares, with 32,700,000 shares pledged[36] - The company issued 630 million RMB convertible bonds, with a conversion price of 12.25 RMB per share, and 6,273,758 bonds were converted into shares[44] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three shareholders alone holding over 25%[36] Operational Efficiency - The company experienced a 65.95% decrease in short-term borrowings, attributed to increased operational cash flow and reduced accounts receivable[11] - The gross profit margin for natural colorants and spices decreased by 3.01% year-on-year, while the gross profit margin for cottonseed products decreased by 2.29%[24] - Total operating costs increased to ¥2,968,337,074.25 from ¥2,476,200,994.05, representing a growth of approximately 19.87% year-over-year[59] - Research and development expenses increased to ¥57,554,798.30 from ¥51,811,347.28, reflecting a growth of approximately 11.4%[59]

晨光生物科技集团股份有限公司 2021 年半年度报告全文 晨光生物科技集团股份有限公司 2021 年半年度报告 2021-099 2021 年 08 月 1 晨光生物科技集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，投 资者及相关人士应当对此保持足够的风险认识，并且应当理解计划、预测与承 诺之间的差异。 报告期，公司无新增加的可能对公司下一报告期经营产生不利影响的重大 | --- | --- | |------------------------------------------------------------------------|------------------------- ...

晨光生物科技集团股份有限公司 2021 年第一季度报告全文 晨光生物科技集团股份有限公司 2021 年第一季度报告 2021-065 2021 年 04 月 1 晨光生物科技集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------|------------------|---------------- ...